Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Nephrology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Nephropathy Clinical Trials

A listing of Nephropathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (26) clinical trials

The standard of care is expected to remain unchanged during this run-in period. Patients whose proteinuria level remains >1 g/24-hours within 2 weeks of the end of the run-in period, who continue to have hematuria, and who meet blood pressure and eGFR criteria will be eligible to enroll in the ...

Phase

Ixazomib for Desensitization

This is a pilot exploratory, proof of concept, open-label, single-center phase II investigator initiated clinical trial entitled IXAzomib for DESensitization (IXADES). The purpose of the study is (1) to examine the safety and efficacy of ixazomib for desensitization of highly sensitized kidney transplant candidates and (2) to conduct mechanistic studies ...

Phase

Sodium Chloride and Contrast Nephropathy

This phase II, open, non-inferiority, randomized and controlled clinical trial is aimed to ascertain the incidence of contrast nephropathy in outpatients undergoing CT scan with contrast. Patients will be randomized to receive oral prophylaxis with capsules of sodium chloride and free water ingestion or prophylaxis with sodium chloride 0.9% intravenous ...

Phase

Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy

Membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults worldwide. The majority of patients will remain stable with either complete remission or partial remission but approximately 20% will progress slowly to end stage renal disease necessitating the need for renal replacement therapy (RRT). Current standard ...

Phase

Trial of Oral Glutamine on Mitochondrial Function in CKD

Chronic kidney disease is associated with endothelial cell dysfunction and muscle wasting contributing to the heightened risk of cardiovascular morbidity, mortality and functional limitation. Accumulation of toxins in renal disease may adversely impact endothelial cell nitric oxide bioavailability and endothelial Nitric Oxide Synthase (eNOS) function consequently heightening oxidative stress and ...

Phase

Hyperbaric Oxygen Therapy for Renal Regeneration in Diabetic Nephropathy

Scientific background Diabetic Kidney Disease (DKD): The kidneys, which are an important target for diabetic induced damage, contribute a lot to this burden. Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide, associated with increased morbidity and mortality in patients with diabetes. The pathogenesis of DKD ...

Phase

Safety Study of IgAN LN MN & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

This is a Phase 2, multicenter study of OMS721 in subjects with the following diseases: IgA Nephropathy (IgAN), Lupus Nephritis, Membranous Nephropathy (MN), or C3 Glomerulopathy, including Dense Deposit Disease. Three cohorts will be enrolled. Cohort 1 will be subjects with corticosteroid dependent IgAN, LN, MN, or C3 Glomerulopathy. Cohort ...

Phase

A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy

Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis worldwide. Several studies indicated that 6-43% of IgA nephropathy patients would develop end-stage kidney disease (ESKD) over a period of 10 years. The clinical risk factors for progression are hypertension, proteinuria, impaired renal function and histologic lesions at ...

Phase

An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients

The purpose of the study is to determine whether an ingestion of a new renal multivitamin supplement can have a beneficial effect on bone and mineral adn inflammation issues related to patients on dialysis.

Phase

Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus

To address the pharmacokinetic profiles of everolimus and tacrolimus in combination in de novo kidney transplant recipients, comparing 1.5 and 3 mg per day of everolimus in fixed doses. For comparison purposes, pharmacokinetic profiles will be performed at first dose (abbreviated), 4th day, 14th day, and 42nd day post-transplantation. Patients ...

Phase